Vaxcyte, Inc.

San Carlos, CA

UEI
Y56EGX9CCTE5
CAGE
71JJ6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
825 Industrial Rd #300, San Carlos, CA 94070, USA
Website
vaxcyte.com
Employees
51-250
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of a universal influenza vaccine produced by cell-free protein synthesis R43AI122375 National Institutes of Health $196,063

Grant subawards

Prime recipient Prime award Amount Awarded
University Of Maryland, Baltimore Broad spectrum Shigella subunit vaccine based on conserved proteins. R01AI161839 $98,628
University Of Maryland, Baltimore Optimization, delineation, evaluation, conduction and engagement of a Shigella. R01AI177142 $324,438
University Of Maryland, Baltimore O-polysaccharide (OPS)-ipaB conjugate vaccine to prevent shigellosis; Optimization, delineation, evaluation, conduction and engagement of a Shigella OPS-IpaB… R01AI177142 $324,438
University Of North Carolina At Chapel Hill Vaxcyte will perform the work outlined in Specific Aim 3 of the study. Besides this work, Vaxcyte will provide protein and conjugates as needed by the… U01AI182180 $1,296,216
University Of Maryland, Baltimore Broad spectrum Shigella subunit vaccine based on conserved proteins; produce purified and provide these proteins to UMB in the amounts requested, analyze and… R01AI161839 $98,628

Latest 5 listed here. See the rest on GovTribe.

About the company

Written by GovTribe AI ·

Vaxcyte, Inc. is a vaccine innovation company dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella.

Vaxcyte, Inc. has not received any prime federal contract awards. As a subcontractor, Vaxcyte, Inc. has provided research and development services for Group A Streptococcus (GAS) conjugate vaccine development, including supplying purified protein samples, developing manufacturing processes, and collaborating on broader vaccine development efforts. These subcontracts have been awarded under programs at the National Institutes of Health, the Centers for Disease Control and Prevention, and other agencies. Partners have included the University of California San Diego, the University of Maryland Baltimore, Boston University, and other research institutions.

As a subgrantee, Vaxcyte, Inc. has also provided research and development services related to Group A Streptococcus and Shigella subunit vaccine development. This has involved supplying purified protein samples, analyzing and developing manufacturing processes, and collaborating on broader vaccine development efforts under programs at the National Institutes of Health and other agencies. Partners have again included the University of California San Diego, the University of Maryland Baltimore, Boston University, and other research institutions.

Quick answers

Is Vaxcyte, Inc. registered in SAM.gov?

Yes. Vaxcyte, Inc.'s SAM.gov registration is active through November 7, 2026.

What is Vaxcyte, Inc.'s most recent federal award?

Vaxcyte, Inc.'s most recent federal grant award is Development of a universal influenza vaccine produced by cell-free protein synthesis (R43AI122375), from National Institutes of Health, on July 7, 2016.

On GovTribe

See Vaxcyte, Inc.'s full federal record

  • Federal grant awards
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login